Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2563
Source ID: NCT00348712
Associated Drug: Rosiglitazone
Title: Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
Acronym:
Status: TERMINATED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: rosiglitazone|DRUG: inhaled human insulin|DRUG: metformin
Outcome Measures: Primary: Treatment difference in HbA1c, After 26 weeks | Secondary: Adverse events, For the duration of the trial|Body weight, For the duration of the trial|Lung function, For the duration of the trial|Blood glucose, For the duration of the trial|Hypoglycaemia, For the duration of the trial
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 301
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2006-10-30
Completion Date: 2008-03-05
Results First Posted:
Last Update Posted: 2017-03-01
Locations: Novo Nordisk Investigational Site, Ebreichsdorf, 2483, Austria|Novo Nordisk Investigational Site, Wien, 1030, Austria|Novo Nordisk Investigational Site, Wien, 1090, Austria|Novo Nordisk Investigational Site, Joensuu, 80130, Finland|Novo Nordisk Investigational Site, Kirkkonummi, 02400, Finland|Novo Nordisk Investigational Site, Turku, FI-20520, Finland|Novo Nordisk Investigational Site, Corbeil Essonnes, 91106, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, 17019, France|Novo Nordisk Investigational Site, Mougins, 06250, France|Novo Nordisk Investigational Site, Nanterre, 92014, France|Novo Nordisk Investigational Site, Narbonne, 11108, France|Novo Nordisk Investigational Site, NEVERS cedex, 58033, France|Novo Nordisk Investigational Site, Pessac, 33600, France|Novo Nordisk Investigational Site, Pointe à Pitre, 97159, France|Novo Nordisk Investigational Site, Roubaix, 59100, France|Novo Nordisk Investigational Site, Tours, 37044, France|Novo Nordisk Investigational Site, Venissieux, 69200, France|Novo Nordisk Investigational Site, Aschaffenburg, 63739, Germany|Novo Nordisk Investigational Site, Augsburg, 86150, Germany|Novo Nordisk Investigational Site, Bad Mergentheim, 97980, Germany|Novo Nordisk Investigational Site, Berlin, 13355, Germany|Novo Nordisk Investigational Site, Darmstadt, 64283, Germany|Novo Nordisk Investigational Site, Dormagen, 41539, Germany|Novo Nordisk Investigational Site, Dresden, 01307, Germany|Novo Nordisk Investigational Site, Duisburg, 47051, Germany|Novo Nordisk Investigational Site, Flörsheim, 65439, Germany|Novo Nordisk Investigational Site, Frankfurt, 60590, Germany|Novo Nordisk Investigational Site, Fulda, 36037, Germany|Novo Nordisk Investigational Site, Genthin, 39307, Germany|Novo Nordisk Investigational Site, Hermaringen, 89568, Germany|Novo Nordisk Investigational Site, Kutenholz-Mulsum, 27449, Germany|Novo Nordisk Investigational Site, Münster, 48145, Germany|Novo Nordisk Investigational Site, Pirna, 01796, Germany|Novo Nordisk Investigational Site, Schkeuditz, 04435, Germany|Novo Nordisk Investigational Site, Wangen, 88239, Germany|Novo Nordisk Investigational Site, Wiesbaden, 65191, Germany|Novo Nordisk Investigational Site, Dublin, DUBLIN 7, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 8, Ireland|Novo Nordisk Investigational Site, Waterford, Ireland|Novo Nordisk Investigational Site, Delft, 2625 AD, Netherlands|Novo Nordisk Investigational Site, Den Haag, 2582 LJ, Netherlands|Novo Nordisk Investigational Site, Den Haag, 2597 AX, Netherlands|Novo Nordisk Investigational Site, Drachten, 9202 NN, Netherlands|Novo Nordisk Investigational Site, Rijswijk, 2281 AK, Netherlands|Novo Nordisk Investigational Site, Roelofarendsveen, 2371 RB, Netherlands|Novo Nordisk Investigational Site, Vlodrop, 6063 DA, Netherlands|Novo Nordisk Investigational Site, Zwijndrecht, 3331 LZ, Netherlands|Novo Nordisk Investigational Site, Alcira, 46600, Spain|Novo Nordisk Investigational Site, Barcelona, 08035, Spain|Novo Nordisk Investigational Site, Gijón, 33206, Spain|Novo Nordisk Investigational Site, Majadahonda, 28222, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, 07010, Spain|Novo Nordisk Investigational Site, Partida de Bacarot, 03114, Spain|Novo Nordisk Investigational Site, Pontevedra, 36071, Spain|Novo Nordisk Investigational Site, Reus, 43201, Spain|Novo Nordisk Investigational Site, San Juan, 03550, Spain|Novo Nordisk Investigational Site, Sevilla, 41009, Spain|Novo Nordisk Investigational Site, Interlaken-Unterseen, 3800, Switzerland|Novo Nordisk Investigational Site, Olten, 4600, Switzerland|Novo Nordisk Investigational Site, Zürich, 8032, Switzerland|Novo Nordisk Investigational Site, Aberdeen, AB25 1LD, United Kingdom|Novo Nordisk Investigational Site, Bath, BA1 2SR, United Kingdom|Novo Nordisk Investigational Site, Belfast, BT12 6BA, United Kingdom|Novo Nordisk Investigational Site, Birmingham, B9 5SS, United Kingdom|Novo Nordisk Investigational Site, Bradford-on-Avon, BA15 1DQ, United Kingdom|Novo Nordisk Investigational Site, Guildford, GU2 7XX, United Kingdom|Novo Nordisk Investigational Site, Hull, HU3 2JZ, United Kingdom|Novo Nordisk Investigational Site, Northampton, NN1 5BD, United Kingdom|Novo Nordisk Investigational Site, Salford, M6 8HD, United Kingdom|Novo Nordisk Investigational Site, Swansea, SA6 6NL, United Kingdom|Novo Nordisk Investigational Site, Trowbridge, BA14 8QA, United Kingdom|Novo Nordisk Investigational Site, Trowbridge, BA14 9AR, United Kingdom|Novo Nordisk Investigational Site, Wirral, Merseyside, CH63 4JY, United Kingdom|Novo Nordisk Investigational Site, York, YO3 7HE, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00348712

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D116 Rosiglitazone small molecule DB00412 Details
D089 Metformin small molecule DB00331 Details